Trichloroacetic acid
PreclinicalSmall molecule
Trichloroacetic acid is one of 48 small molecule programs targeting Epistaxis. It is currently in Preclinical.
2
Indications
8
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
113 competitors in Alopecia Areata
#DrugCompanyPhaseTrials
1Olumiant
Eli LillyPhase 3
Opzelura
PfizerPhase 3
Rinvoq
AbbViePhase 3
PF-06651600
PfizerPhase 3
Jaktinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Velsipity
PfizerPhase 2
Jakafi
IncytePhase 2
SHR0302
RReistone Biopharma Company Limited
Phase 3
IL2
AAssistance Publique - Hôpitaux de Paris
Phase 3
Adtralza
LEO PharmaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Alopecia Areata1 trial
New Treatment of Alopecia Areata
Completed·—·N/A·NCT05594316·40 enrolled
Trichloroacetic Acid1 trial
Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid
Unknown status·—·Phase 4·NCT03153852·30 enrolled
Metformin1 trial
USE THE SYSTEMIC METFORMIN IN MELASMA
Unknown status·—·Phase 4·NCT03475524·60 enrolled
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Trichloroacetic acid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIndonesia University